IP Library Assignment 069359/0921
Patent Assignment
Reel/Frame 069359/0921

Release of Security Interest

Recorded: 2024-11-14 Pages: 25
Assignor
Assignees
NEURELIS, INC.
3430 CARMEL MOUNTAIN ROAD, SUITE 300, SAN DIEGO, CALIFORNIA, 92121
AEGIS THERAPEUTICS, LLC
3430 CARMEL MOUNTAIN ROAD, SUITE 300, SAN DIEGO, CALIFORNIA, 92121
Covered Properties (71)
Absorption Enhancers for Drug Administration
Application: 16/898,365 →
Publication: US US20210121573A1
Compositions, Devices and Methods for the Treatment of Alcohol Use Disorder
Application: 16/311,944 →
Publication: US US20190209464A1
Compositions, Devices, and Methods for the Treatment of Opioid-Receptor-Mediated Conditions
Application: 17/024,149 →
Publication: US US20210077382A1
Formulations and Methods for the Prevention of Opioid Overdose
Application: 17/055,647 →
Publication: US US20210220346A1
Compositions, Devices, and Methods for the Treatment of Overdose and Reward-Based Disorders
Application: 16/721,872 →
Publication: US US20200390691A1
Peptide Compositions and Methods of Use
Application: 16/615,362 →
Publication: US US20200197494A1
Compositions for Drug Administration
Application: 16/678,347 →
Publication: US US20200138956A1
Oil-Soluble Drug Containing Compositions and Methods of Use Thereof
Application: 16/875,683 →
Publication: US US20200360292A1
Methods and Compositions for Rapid Delivery of Anti-Seizure Therapeutics
Application: 63/135,291 →
Multimodal Particulate Formulations
Application: 16/594,897 →
Publication: US US20200038320A1
Administration of Benzodiazepine Compositions
Application: 17/228,514 →
Publication: US US20220062227A1
Administration of Benzodiazepine Compositions
Application: 17/332,800 →
Publication: US US20210299089A1
Administration of Benzodiazepine Compositions
Application: 17/336,389 →
Publication: US US20220117887A1
Methods and Compositions for Treating Seizure Disorders in Pediatric Patients
Application: 63/209,092 →
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Application: 17/114,335 →
Publication: US US20210290635A1
Intranasal Epinephrine Formulations and Methods for the Treatment of Disease
Application: 17/396,044 →
Publication: US US20210361770A1
Methods and Compositions for Rapid Delivery of Anti-Seizure Therapeutics
Application: 63/276,760 →
Methods and Compositions for Rapid Delivery of Anti-Seizure Therapeutics
Application: 17/570,535 →
Publication: US US20220218598A1
Compositions and Methods for Single Dose Anti-Seizure Therapeutics
Application: 63/276,761 →
Administration of Benzodiazepine Compositions
Application: 17/721,595 →
Publication: US US20220241187A1
Intranasal Olanzapine Formulations and Methods of Their Use
Application: 63/323,592 →
Rho Kinase Inhibitor Ba-1049 (R) and Active Metabolites Thereof
Application: 17/381,500 →
Publication: US US20220089567A1
Methods and Compositions for Increasing Interseizure Cluster Interval Duration
Application: 63/284,033 →
Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
Application: 17/319,221 →
Publication: US US20210275444A1
Compositions and Methods for the Treatment of Opioid Overdose
Application: 63/229,300 →
Compositions and Methods for the Treatment of Opioid Overdose
Application: 17/881,191 →
Publication: US US20220387306A1
Administration of Benzodiazepine Compositions
Application: 18/062,062 →
Publication: US US20230104144A1
Intranasal Olanzapine Formulations and Methods of Their Use
Application: 18/125,940 →
Publication: US US20230301903A1
Methods and Compositions for Treating Seizure Disorders in Pediatric Patients
Application: 17/837,198 →
Publication: US US20220401456A1
Polymorphs of Substituted Isoquinoline-Based Rho Kinase Inhibitors
Application: 63/350,936 →
Absorption Enhancers for Intranasal Interferon Administration
Patent: 8,551,468 →
Application: 12/189,722 →
Publication: US US20080299079A1
Absorption Enhancers for Intranasal Administration
Patent: 8,927,497 →
Application: 13/371,274 →
Publication: US US20120196941A1
Pharmaceutical Composition Including Alkyl Glycoside and an Anti-Seizure Agent
Patent: 9,642,913 →
Application: 14/152,686 →
Publication: US US20140128479A1
Antibacterial Compositions for Drug Administration
Patent: 9,114,069 →
Application: 12/512,862 →
Publication: US US20100068209A1
Controlled Release Formulations
Patent: 8,329,220 →
Application: 12/197,179 →
Publication: US US20090110735A1
Controlled Release Formulations
Patent: 8,470,370 →
Application: 13/688,116 →
Publication: US US20130089595A1
Intranasal Administration of Active Agents to the Central Nervous System
Patent: 8,883,728 →
Application: 12/954,219 →
Publication: US US20110129462A1
Compositions for Drug Administration
Patent: 8,642,564 →
Application: 12/036,963 →
Publication: US US20080200418A1
Alkylglycoside Compositions for Drug Administration
Patent: 8,268,791 →
Application: 12/341,696 →
Publication: US US20090163447A1
Compositions for Drug Administration
Patent: 8,440,631 →
Application: 12/645,376 →
Publication: US US20100160378A1
Compositions for Drug Administration
Patent: 9,283,280 →
Application: 13/893,219 →
Publication: US US20130253009A1
Compositions for Oral Drug Administration
Application: 15/655,669 →
Publication: US US20180104344A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 7,425,542 →
Application: 11/474,055 →
Publication: US US20070298010A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 8,076,290 →
Application: 11/937,966 →
Publication: US US20100209485A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 8,084,022 →
Application: 12/050,038 →
Publication: US US20080194461A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 7,998,927 →
Application: 12/119,378 →
Publication: US US20080268032A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 8,133,863 →
Application: 12/360,758 →
Publication: US US20090197816A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 8,772,231 →
Application: 12/896,640 →
Publication: US US20110020435A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 8,226,949 →
Application: 12/618,558 →
Publication: US US20100124567A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 8,846,044 →
Application: 13/544,851 →
Publication: US US20130039851A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 9,446,134 →
Application: 14/494,990 →
Publication: US US20150216980A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Application: 15/264,393 →
Publication: US US20170216397A1
Compositions for Drug Administration
Patent: 9,895,444 →
Application: 14/133,350 →
Publication: US US20140107145A1
Absorption Enhancers for Drug Administration
Application: 15/942,110 →
Publication: US US20180221489A1
Stabilizing Alkylglycoside Compositions and Methods Thereof
Patent: 8,173,594 →
Application: 12/491,932 →
Publication: US US20090305958A1
Compositions for Drug Administration
Application: 15/890,131 →
Publication: US US20180169247A1
Intranasal Epinephrine Formulations and Methods for the Treatment of Disease
Application: 16/420,044 →
Publication: US US20190269781A1
Multimodal Particulate Formulations
Patent: 8,530,463 →
Application: 12/266,529 →
Publication: US US20090130216A1
Administration of Benzodiazepine Compositions
Patent: 8,895,546 →
Application: 13/495,942 →
Publication: US US20130065886A1
Administration of Benzodiazepine Compositions
Patent: 9,763,876 →
Application: 14/527,613 →
Publication: US US20150065491A1
4-Substituted Piperidine Derivatives
Patent: 7,572,913 →
Application: 11/065,696 →
Publication: US US20050272751A1
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Patent: 9,687,483 →
Application: 15/006,314 →
Publication: US US20160213664A1
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Application: 15/590,815 →
Publication: US US20170246181A1
Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Application: 16/214,973 →
Publication: US US20190298733A1
Rho Kinase Inhibitor Ba-1049 (R) and Active Metabolites Thereof
Application: 15/591,039 →
Publication: US US20170313680A1
Rho Kinase Inhibitor Ba-1049 (R) and Active Metabolites Thereof
Application: 15/988,736 →
Publication: US US20180297982A1
Kinase Inhibitors for Treatment of Disease
Application: 16/032,442 →
Publication: US US20190015404A1
Intranasal Epinephrine Formulations and Methods for the Treatment of Disease
Application: 16/869,461 →
Publication: US US20200261582A1
Rho Kinase Inhibitor Ba-1049 (R) and Active Metabolites Thereof
Application: 16/735,359 →
Publication: US US20200199105A1
Compositions and Methods for the Treatment of Opioid Overdose
Application: 16/461,354 →
Publication: US US20200060967A1
Oil-Soluble Drug Containing Compositions and Methods of Use Thereof
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Oct 7, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050644/0136 →
Assignment of Assignor's Interest Oct 7, 2019
From: CARTT, STEVE; MEDEIROS, DAVID
To: HALE BIOPHARMA VENTURES, LLC
Reel/Frame 050644/0198 →
Assignment of Assignor's Interest Oct 16, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050740/0096 →
Assignment of Assignor's Interest Oct 16, 2019
From: CRYSTAL, ROGER; AGRAWAL, ARVIND
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050740/0107 →
Assignment of Assignor's Interest Nov 11, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 050976/0039 →
Assignment of Assignor's Interest Jul 24, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 053305/0980 →
Assignment of Assignor's Interest Jul 24, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 053306/0366 →
Assignment of Assignor's Interest Aug 6, 2020
From: CRYSTAL, ROGER; ELLISON, MARK; SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 053419/0829 →
Assignment of Assignor's Interest Aug 6, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 053419/0262 →
Assignment of Assignor's Interest Dec 3, 2020
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 054526/0623 →
Assignment of Assignor's Interest Dec 3, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 054526/0647 →
Security Interest Dec 10, 2020
From: OPIANT PHARMACEUTICALS, INC.
To: PONTIFAX MEDISON FINANCE GP, L.P.
Reel/Frame 054602/0192 →
Assignment of Assignor's Interest Jan 14, 2021
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS LLC
Reel/Frame 054915/0209 →
Assignment of Assignor's Interest Jan 14, 2021
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 054915/0020 →
Assignment of Assignor's Interest Jan 14, 2021
From: SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 054915/0123 →
Assignment of Assignor's Interest Mar 18, 2021
From: MAGGIO, EDWARD T.
To: NEURELIS, INC.
Reel/Frame 055633/0147 →
Assignment of Assignor's Interest Mar 18, 2021
From: MADDEN, STUART
To: NEURELIS, INC.
Reel/Frame 055634/0171 →
Assignment of Assignor's Interest Apr 6, 2021
From: HALE BIOPHARMA VENTURES, LLC
To: NEURELIS, INC.
Reel/Frame 055835/0062 →
Assignment of Assignor's Interest May 13, 2021
From: CRYSTAL, ROGER; SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 056227/0902 →
Nunc Pro Tunc Assignment Jun 8, 2021
From: NEURELIS, INC.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 056514/0844 →
Nunc Pro Tunc Assignment Jun 8, 2021
From: MAGGIO, EDWARD T.
To: NEURELIS, INC.
Reel/Frame 056514/0791 →
Assignment of Assignor's Interest Jun 16, 2021
From: CARRAZANA, ENRIQUE J.
To: NEURELIS, INC.
Reel/Frame 056563/0553 →
Assignment of Assignor's Interest Jun 16, 2021
From: RABINOWICZ, ADRIAN L.
To: NEURELIS, INC.
Reel/Frame 056563/0500 →
Assignment of Assignor's Interest Jul 7, 2021
From: ROSEN, KENNETH M.; RIESINGER, STEVEN WAYNE; MCKERRACHER, LISA; BOND MORITZ, LISA
To: BIOAXONE BIOSCIENCES, INC.
Reel/Frame 056773/0985 →
Assignment of Assignor's Interest Jul 21, 2021
From: ROSEN, KENNETH M.; ABBINANTI, MATTHEW D.; RUSCHEL, JOERG; MCKERRACHER, LISA
To: BIOAXONE BIOSCIENCES, INC.
Reel/Frame 056932/0377 →